Related Experiment Video

Updated: Jun 14, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Treatment of ovarian cancer by monoclonal antibodies

Seiji Mabuchi1, Tadashi Kimura

  • 1Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan. smabumabu@hotmail.com

Discovery Medicine
|March 31, 2010
PubMed

Insights

Monoclonal antibodies (mAb) show promise for treating ovarian cancer by targeting tumor cells. However, their clinical effectiveness in ovarian cancer patients requires further investigation despite encouraging preclinical results.

Area of Science:

  • Gynecological Oncology
  • Immunotherapy
  • Cancer Therapeutics

Background:

  • Ovarian cancer is the deadliest gynecological malignancy, with limited treatment options despite advances.
  • Monoclonal antibodies (mAb) offer targeted therapy, potentially reducing side effects compared to chemotherapy.
  • While mAb show promise in preclinical ovarian cancer studies, clinical efficacy remains unproven.

Purpose of the Study:

  • To review the current status of monoclonal antibody (mAb) therapy for ovarian cancer.
  • To evaluate the potential of mAb as a targeted treatment strategy for ovarian cancer.
  • To identify areas for future research in mAb-based ovarian cancer treatment.

Main Methods:

  • Review of preclinical studies on mAb for ovarian cancer.
  • Analysis of clinical trial data (Phase I/II) for mAb in ovarian cancer patients.
  • Comparison of mAb efficacy in ovarian cancer versus other malignancies.

Main Results:

  • Preclinical studies demonstrate encouraging therapeutic effects of mAb on ovarian cancer.
  • Some mAb have shown favorable outcomes in early-phase clinical trials for ovarian cancer.
  • mAb therapy has not yet demonstrated convincing clinical effectiveness in ovarian cancer compared to other cancers.

Conclusions:

  • Monoclonal antibodies (mAb) represent a promising avenue for ovarian cancer treatment.
  • Further research is essential to develop more effective and specific mAb therapies for ovarian cancer.
  • Optimizing mAb strategies is crucial to improve patient outcomes in ovarian cancer management.

More Related Videos

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-107:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...